Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Accumulated Expenses (2020 - 2022)

Atea Pharmaceuticals has reported Accumulated Expenses over the past 3 years, most recently at $4.4 million for Q3 2022.

  • Quarterly results put Accumulated Expenses at $4.4 million for Q3 2022, up 51.4% from a year ago — trailing twelve months through Sep 2022 was $4.4 million (up 51.4% YoY), and the annual figure for FY2021 was $4.2 million, down 70.71%.
  • Accumulated Expenses for Q3 2022 was $4.4 million at Atea Pharmaceuticals, up from $3.2 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for AVIR hit a ceiling of $24.8 million in Q1 2022 and a floor of $824000.0 in Q1 2021.
  • Median Accumulated Expenses over the past 3 years was $4.2 million (2021), compared with a mean of $7.0 million.
  • Biggest five-year swings in Accumulated Expenses: tumbled 70.71% in 2021 and later skyrocketed 2914.56% in 2022.
  • Atea Pharmaceuticals' Accumulated Expenses stood at $14.4 million in 2020, then tumbled by 70.71% to $4.2 million in 2021, then rose by 4.42% to $4.4 million in 2022.
  • The last three reported values for Accumulated Expenses were $4.4 million (Q3 2022), $3.2 million (Q2 2022), and $24.8 million (Q1 2022) per Business Quant data.